Skip to main content
Erschienen in: Journal of Infection and Chemotherapy 6/2012

01.12.2012 | Original Article

Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study

verfasst von: Shigeatsu Endo, Yasushi Suzuki, Gaku Takahashi, Tatsuyori Shozushima, Hiroyasu Ishikura, Akira Murai, Takeshi Nishida, Yuhei Irie, Masanao Miura, Hironobu Iguchi, Yasuo Fukui, Kimiaki Tanaka, Tsuyoshi Nojima, Yoshikazu Okamura

Erschienen in: Journal of Infection and Chemotherapy | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

The clinical usefulness of presepsin for discriminating between bacterial and nonbacterial infections (including systemic inflammatory response syndrome) was studied and compared with procalcitonin (PCT) and interleukin-6 (IL-6) in a multicenter prospective study. Suspected sepsis patients (n = 207) were enrolled into the study. Presepsin levels in patients with systemic bacterial infection and localized bacterial infection were significantly higher than in those with nonbacterial infections. In addition, presepsin, PCT, and IL-6 levels in patients with bacterial infectious disease were significantly higher than in those with nonbacterial infectious disease (P < 0.0001, P < 0.0001, and P < 0.0001, respectively). The area under the receiver operating characteristic curve was 0.908 for presepsin, 0.905 for PCT, and 0.825 for IL-6 in patients with bacterial infectious disease and those with nonbacterial infectious disease. The cutoff value of presepsin for discrimination of bacterial and nonbacterial infectious diseases was determined to be 600 pg/ml, of which the clinical sensitivity and specificity were 87.8 % and 81.4 %, respectively. Presepsin levels did not differ significantly between patients with gram-positive and gram-negative bacterial infections. The sensitivity of blood culture was 35.4 %; that for presepsin was 91.9 %. Also there were no significant differences in presepsin levels between the blood culture-positive and -negative groups. Consequently, presepsin is useful for the diagnosis of sepsis, and it is superior to conventional markers and blood culture.
Literatur
1.
Zurück zum Zitat Meisner M. Pathobiochemistry and clinical use of procalcitonin. 2002;323(1-2):17–29. Meisner M. Pathobiochemistry and clinical use of procalcitonin. 2002;323(1-2):17–29.
2.
Zurück zum Zitat Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, et al. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother. 2005;11:152–9.PubMedCrossRef Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, et al. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother. 2005;11:152–9.PubMedCrossRef
3.
Zurück zum Zitat Endo S, Aikawa N, Fujishima S, Sekine I, Kogawa K, Yamamoto Y, et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother. 2008;14:244–9.PubMedCrossRef Endo S, Aikawa N, Fujishima S, Sekine I, Kogawa K, Yamamoto Y, et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother. 2008;14:244–9.PubMedCrossRef
4.
Zurück zum Zitat Endo S, Sato N, Suzuki Y, Kojika M, Takahashi G, Yamada Y, et al. Significance of measuring procalcitonin values for diagnosis of sepsis. J Jpn Soc Surg Infect 2007;4(3):112–120 (in Japanese) Endo S, Sato N, Suzuki Y, Kojika M, Takahashi G, Yamada Y, et al. Significance of measuring procalcitonin values for diagnosis of sepsis. J Jpn Soc Surg Infect 2007;4(3):112–120 (in Japanese)
5.
Zurück zum Zitat Furusako S, Shirakawa K. Methods for detecting human low molecular weight CD14. United States patent 2008; US7465547 B2. Furusako S, Shirakawa K. Methods for detecting human low molecular weight CD14. United States patent 2008; US7465547 B2.
6.
Zurück zum Zitat Furusako S, Shirakawa K, Hirose J. Soluble CD14 antigen. United States patent 2009; US7608684 B2. Furusako S, Shirakawa K, Hirose J. Soluble CD14 antigen. United States patent 2009; US7608684 B2.
7.
Zurück zum Zitat Naitoh K, Shirakawa K, Hirose J, Nakamura M, Takeuchi T, Hosaka Y, et al. The new sepsis marker, sCD14-ST (PRESEPSIN): induction mechanism in the rabbit sepsis models. SEPSIS 2010, Poster P-19. Naitoh K, Shirakawa K, Hirose J, Nakamura M, Takeuchi T, Hosaka Y, et al. The new sepsis marker, sCD14-ST (PRESEPSIN): induction mechanism in the rabbit sepsis models. SEPSIS 2010, Poster P-19.
8.
Zurück zum Zitat Nakamura M, Takeuchi T, Naito K, Shirakawa K, Hosaka Y, Yamasaki F, et al. Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model. Crit Care. 2008;12(suppl 2):P194. doi:10.1186/cc6415.CrossRef Nakamura M, Takeuchi T, Naito K, Shirakawa K, Hosaka Y, Yamasaki F, et al. Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model. Crit Care. 2008;12(suppl 2):P194. doi:10.​1186/​cc6415.CrossRef
9.
Zurück zum Zitat Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11(5):234–8.PubMedCrossRef Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11(5):234–8.PubMedCrossRef
10.
Zurück zum Zitat Kojika M, Takahashi G, Matsumoto N, Kikkawa T, Hoshikawa K, Shioya N, et al. Serum levels of soluble CD14 subtype reflect the APACHE II and SOFA Scores. Med Postgrad. 2010;48(1):46–50. Kojika M, Takahashi G, Matsumoto N, Kikkawa T, Hoshikawa K, Shioya N, et al. Serum levels of soluble CD14 subtype reflect the APACHE II and SOFA Scores. Med Postgrad. 2010;48(1):46–50.
11.
Zurück zum Zitat Takahashi G, Suzuki Y, Kojika M, Matsumoto N, Shozushima T, Makabe H, et al. Evaluation of responses to IVIG therapy in patients with severe sepsis and septic shock by soluble CD14 subtype monitoring. Med Postgrad. 2010;48(1):19–24. Takahashi G, Suzuki Y, Kojika M, Matsumoto N, Shozushima T, Makabe H, et al. Evaluation of responses to IVIG therapy in patients with severe sepsis and septic shock by soluble CD14 subtype monitoring. Med Postgrad. 2010;48(1):19–24.
12.
Zurück zum Zitat Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17(6):764–9.PubMedCrossRef Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17(6):764–9.PubMedCrossRef
13.
Zurück zum Zitat Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644–55.PubMedCrossRef Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644–55.PubMedCrossRef
14.
Zurück zum Zitat Kurihara T, Yanagida A, Yokoi H, Koyata A, Matsuya T, Ogawa J, et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem. 2008;375(1):144–6.PubMedCrossRef Kurihara T, Yanagida A, Yokoi H, Koyata A, Matsuya T, Ogawa J, et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem. 2008;375(1):144–6.PubMedCrossRef
15.
Zurück zum Zitat Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta. 2011;412(23–24):2157–61.PubMedCrossRef Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta. 2011;412(23–24):2157–61.PubMedCrossRef
16.
Zurück zum Zitat Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296–327.PubMedCrossRef Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296–327.PubMedCrossRef
Metadaten
Titel
Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study
verfasst von
Shigeatsu Endo
Yasushi Suzuki
Gaku Takahashi
Tatsuyori Shozushima
Hiroyasu Ishikura
Akira Murai
Takeshi Nishida
Yuhei Irie
Masanao Miura
Hironobu Iguchi
Yasuo Fukui
Kimiaki Tanaka
Tsuyoshi Nojima
Yoshikazu Okamura
Publikationsdatum
01.12.2012
Verlag
Springer Japan
Erschienen in
Journal of Infection and Chemotherapy / Ausgabe 6/2012
Print ISSN: 1341-321X
Elektronische ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-012-0435-2

Weitere Artikel der Ausgabe 6/2012

Journal of Infection and Chemotherapy 6/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.